Compare · COLL vs LLY
COLL vs LLY
Side-by-side comparison of Collegium Pharmaceutical Inc. (COLL) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COLL and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.11T, about 948.9x COLL ($1.17B).
- Over the past year, COLL is up 16.7% and LLY is up 54.7% - LLY leads by 38.0 points.
- LLY has been more active in the news (5 items in the past 4 weeks vs 1 for COLL).
- LLY has more recent analyst coverage (25 ratings vs 20 for COLL).
- Company
- Collegium Pharmaceutical Inc.
- Eli Lilly and Company
- Price
- $36.09-0.50%
- $1178.57+0.73%
- Market cap
- $1.17B
- $1.11T
- 1M return
- +4.19%
- +5.00%
- 1Y return
- +16.72%
- +54.73%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- News (4w)
- 1
- 5
- Recent ratings
- 20
- 25
Collegium Pharmaceutical Inc.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest COLL
- Amendment: Collegium Pharmaceutical Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- Director Santini Gino exercised 8,700 shares at a strike of $16.49, increasing direct ownership by 8% to 112,483 units (SEC Form 4)
- Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form S-8 filed by Collegium Pharmaceutical Inc.
- SEC Form S-8 filed by Collegium Pharmaceutical Inc.
- Collegium to Participate in 2026 Jefferies Global Healthcare Conference
- Director Freund John Gordon sold $681 worth of shares (20 units at $34.05), decreasing direct ownership by 0.02% to 83,952 units (SEC Form 4)
- Director Bohlin Garen G was granted 8,741 shares, increasing direct ownership by 14% to 71,000 units (SEC Form 4)
- Director Freund John Gordon was granted 8,741 shares, exercised 8,700 shares at a strike of $16.49 and sold $142,547 worth of shares (4,127 units at $34.54), increasing direct ownership by 19% to 83,972 units (SEC Form 4)
- Director Paya Carlos V was granted 8,741 shares, increasing direct ownership by 45% to 28,323 units (SEC Form 4)
Latest LLY
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
- Three Biotechs Deliver Catalysts to Watch
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
- Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
- What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
- Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
- SEC Form 11-K filed by Eli Lilly and Company
- Lilly declares third-quarter 2026 dividend